A retrospective study to evaluate clinical outcomes for patients who received check point inhibitor therapy with pembrolizumab or nivolumab and routine vaccinations
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Jul 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology